Aimmune Therapeutics Inc. won the qualified backing of members of the FDA's Allergenic Products Advisory Committee (adcom) during a Friday meeting held to discuss whether or not safety and efficacy data support licensure of Palforzia (AR-101), the company's oral immunotherapy (OIT) to reduce the incidence and severity of allergic reactions to peanut.